NanaBidialTM is an investigative new product containing 20 mg/mL of Cannabidiol (CBD) and and <1mg/mL of delta-9-tetrahydrocannabinol (THC), in a sub-micron spray applied to the oro-buccal membrane.
NanaBidialTM Interim Guidance to Practitioner can be found here..
The consumer medical information (CMI) is available here (ENGLISH)
https://www.tga.gov.au/access-medicinal-cannabis-products-steps-using-access-schemes
https://www.tga.gov.au/access-medicinal-cannabis-products-steps-using-access-schemes#step2
Requirements in each Australian state for prescribers to gain access to Schedule 8 Medicinal Cannabis
Overview
State / Territory |
Required document (form) to be submitted |
Public document |
ACT |
Application for approval to prescribe medicinal cannabis |
YES |
NSW |
TGA Special Access Scheme – Category B (Medicinal Cannabis NSW) |
YES |
NT |
Notification of Supply of an Unrestricted S8 Substance |
YES |
TAS |
Authorisation to prescribe medical cannabis (unregistered cannabinoid products) |
NO |
QLD |
Application for a Medicinal Cannabis Approval |
YES |
SA |
Authority Application to prescribe a Schedule 8 medicinal cannabis drug |
YES |
VIC |
Application for a Schedule 8 treatment permit |
Online Form |
WA |
Application for authorisation - Cannabis Based Products |
YES |
Description
State / Territory |
Requirements and procedures |
Link to documents |
ACT |
On 2 March 2018, the NSW and Commonwealth governments announced a change in the prescribing process in NSW to improve individual patient access to unregistered cannabis medicines by introducing a single application process. NSW Health relies on a single clinical assessment by the Therapeutic Goods Administration (TGA) under the Special Access Scheme and confines its review to checking the credentials of the prescribing doctor and the patient history, as with any other Schedule 8 drug authority. The joint application form captures both the relevant requirements for the TGA SAS Category B application and the NSW Health authority application form. Medical practitioners must submit the application to the TGA but are not required to also provide a copy of the application form to NSW Health. Pharmacists may need to apply to the TGA and the Office of Drug Control to seek approval to obtain medicinal cannabis. |
Application for approval:
General information:
|
NSW |
On 2 March 2018, the NSW and Commonwealth governments announced a change in the prescribing process in NSW to improve individual patient access to unregistered cannabis medicines by introducing a single application process. NSW Health relies on a single clinical assessment by the Therapeutic Goods Administration (TGA) under the Special Access Scheme and confines its review to checking the credentials of the prescribing doctor and the patient history, as with any other Schedule 8 drug authority. The joint application form captures both the relevant requirements for the TGA SAS Category B application and the NSW Health authority application form. Medical practitioners must submit the application to the TGA but are not required to also provide a copy of the application form to NSW Health. |
Information: Special Access Scheme: NSW/TGA medicinal cannabis forms
Note: No requirement to provide a copy of this application form to NSW Health
SAS online system |
Northern Territory |
To date the NT has not applied additional controls to pharmaceutical cannabis products. Authorisation from NT Chief Health Officer (CHO) is not required for all goods in Schedule 8 other than the ones declared as restricted (see link for a full list). However, a prescriber needs to send a notification to the NT CHO if the patient is going to be on the unrestricted S8 medicine for more than 8 weeks, or has already been on the medicine for 8 weeks with another prescriber (notification form on the NTG website). |
Notification: Medical practitioners and schedule 8 medicines
|
Tasmania |
The Tasmanian Government has developed a medical cannabis controlled access scheme (CAS). The scheme will allow only relevant medical specialists to be authorised to prescribe medical cannabis (unregistered cannabinoid products) in limited circumstances where conventional treatment has been unsuccessful. Please note that only public hospital consultants or visiting medical officers/VMOs (medical practitioners in private practice who also provide medical services in a public hospital) can be approved to prescribe these products. If a GP believes an unregistered medical cannabis product is indicated based on a risk/benefit assessment, referral to a relevant specialist medical practitioner in the relevant field of medicine is required. The Relevant Specialist Medical Practitioner must then apply to the Secretary of the Tasmanian Department of Health and Human Services (DHHS), for authorisation to prescribe unregistered medicinal cannabis products. Please note that the application form is available on the Tasmanian Health System (THS) intranet page (it is not a public document). The application is reviewed by a delegate of the Secretary of DHHS under the Poisons Act 1971. Application or notification to the TGA and/or the Office of Drug Control is required in parallel. Once the authority to prescribe unregistered medicinal cannabis products is issued, the Relevant Specialist Medical Practitioner prescribes a product for a patient in accordance with their authority and the product is dispensed by a Tasmanian Health Service (THS) Hospital Pharmacy. |
General information: Unregistered Medical Cannabis Products Access Flowchart - For Health Professionals And Department of Health and Human Services And |
Queensland |
A medical practitioner must apply to the Chief Executive (CE), Department of Health, for a medicinal cannabis approval in Queensland. This approval authorises the medical practitioner to treat an individual patient with a specified medicinal cannabis product. The CE may request advice from the Queensland Medicinal Cannabis Expert Advisory Panel. Specialists that wish to become a patient-class prescriber will need patient-class approval. Once the medicinal cannabis approval is granted, it is valid for up to one year. The prescriber must then apply to the TGA for supply of the product under SAS scheme or AP scheme, before the medicinal cannabis product can be prescribed (medical practitioner) and dispensed (pharmacist) to the patient. |
Application for approval: Prescribing medicinal cannabis
Further information:
SAS online system
|
South Australia |
A medical practitioner in South Australia must apply for approval to prescribe a Schedule 8 medicinal cannabis drug through the Drugs of Dependence Unit. Schedule 8 medicinal cannabis products are being treated in the same way as other schedule 8 drugs, i.e. medical practitioners must apply for a Controlled Substances Act authority to legally prescribe the drug. This covers the prescriber under South Australia’s controlled substances legislation. |
Application for approval:
Further information: |
Victoria |
A medical practitioner must obtain a Schedule 8 treatment permit from the Victorian Department of Health & Human Services before prescribing a Schedule 8 medicinal cannabis product in Victoria. Treatment permits to prescribe an unapproved medicinal cannabis product will generally only be approved where the applicant has obtained TGA approval to prescribe that product to the patient. |
Application for permit: Victorian Schedule 8 Treatment permit And
Further information:
SAS online system |
Western Australia |
Approval from the WA Department of Health is required to prescribe any cannabis-based product in Schedule 8. There are two pathways: • Notification pathway - specialist prescribers can apply for a class approval • Authorisation pathway - specialists can apply for treatment of individual patients on the basis of other indications. The notification pathway is currently limited to treatment of multiple sclerosis, but is likely to be expanded as evidence accumulates for efficacy in other conditions. A specialist can appoint a General Practitioner as a co-prescriber. A patient can present an approved prescription to any WA pharmacy for dispensing. Pharmacies can obtain products from licensed manufacturers or approved sponsors acting as pharmaceutical wholesalers |
Application for authorisation: Government of Western Australia
Further information: Government of Western Australia |
Summary S8 Medicinal Cannabis Products – state level
State / Territory
|
GPs |
Specialists |
Process |
|
ACT |
|
Yes, with specialist support |
Yes |
Specific process |
NSW |
|
Yes |
Yes |
Application to TGA (SAS Category B), No application to NSW Health |
NT |
|
Initial application made by specialist, then GP ongoing |
Yes |
Standard S8 process |
TAS |
|
No |
Yes |
Specific process |
QLD |
Single patient |
Yes, with longitudinal treating relationship with the patient |
Yes |
Application to CE of QLD Health |
Patient class (CINV, palliative care, resistant paediatric epilepsy) |
No |
Yes (certain specialists) |
Must follow QLD clinical guidance (no application) |
|
SA |
|
Yes, with specialist support |
Yes |
Standard S8 process |
VIC |
General S8 |
Yes
|
Yes |
Standard S8 process |
WA |
Authorisation (like TGA SAS CatB) |
Yes, with specialist support |
Yes |
Specific process |
Notification (like TGA AP Scheme) |
Initial application made by specialist, then GP ongoing |
Yes |
Specific process |
Access to medicinal cannabis products: Assistance for Doctors re SAS and AP
Medicinal Cannabis Section at TGA:
call 1800 220 007 (or 02 6232 8866),
or email to: [email protected],
or seek further information available on the following websites:
Special Access Scheme: NSW/TGA medicinal cannabis forms
https://www.tga.gov.au/access-medicinal-cannabis-products
https://www.odc.gov.au/medicinal-cannabis
https://www.tga.gov.au/access-medicinal-cannabis-products-steps-using-access-schemes